The stock has a 36-month beta value of 0.27. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KNSA is 39.72M, and at present, short sellers hold a 8.20% of that float. On December 27, 2024, the average trading volume of KNSA was 308.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KNSA) stock’s latest price update
The stock of Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) has increased by 0.85 when compared to last closing price of 19.94. Despite this, the company has experienced a 0.25% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-26 that LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.
KNSA’s Market Performance
KNSA’s stock has risen by 0.25% in the past week, with a monthly drop of -7.75% and a quarterly drop of -16.07%. The volatility ratio for the week is 3.01% while the volatility levels for the last 30 days are 3.31% for Kiniksa Pharmaceuticals International Plc The simple moving average for the past 20 days is -3.69% for KNSA’s stock, with a -8.17% simple moving average for the past 200 days.
Analysts’ Opinion of KNSA
Many brokerage firms have already submitted their reports for KNSA stocks, with Jefferies repeating the rating for KNSA by listing it as a “Buy.” The predicted price for KNSA in the upcoming period, according to Jefferies is $40 based on the research report published on September 13, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see KNSA reach a price target of $34. The rating they have provided for KNSA stocks is “Overweight” according to the report published on May 03rd, 2024.
BofA Securities gave a rating of “Buy” to KNSA, setting the target price at $40 in the report published on June 29th of the previous year.
KNSA Trading at -10.51% from the 50-Day Moving Average
After a stumble in the market that brought KNSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.56% of loss for the given period.
Volatility was left at 3.31%, however, over the last 30 days, the volatility rate increased by 3.01%, as shares sank -8.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.68% lower at present.
During the last 5 trading sessions, KNSA rose by +0.25%, which changed the moving average for the period of 200-days by -1.61% in comparison to the 20-day moving average, which settled at $20.88. In addition, Kiniksa Pharmaceuticals International Plc saw 14.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KNSA starting from Tessari Eben, who sale 23,017 shares at the price of $20.44 back on Dec 16 ’24. After this action, Tessari Eben now owns 95,975 shares of Kiniksa Pharmaceuticals International Plc, valued at $470,467 using the latest closing price.
Tessari Eben, the Officer of Kiniksa Pharmaceuticals International Plc, proposed sale 23,017 shares at $20.44 during a trade that took place back on Dec 16 ’24, which means that Tessari Eben is holding shares at $470,373 based on the most recent closing price.
Stock Fundamentals for KNSA
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.61 for the gross margin
The net margin for Kiniksa Pharmaceuticals International Plc stands at -0.02. The total capital return value is set at -0.06. Equity return is now at value -2.15, with -1.75 for asset returns.
Based on Kiniksa Pharmaceuticals International Plc (KNSA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 5.54. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -14.32.
Currently, EBITDA for the company is -22.86 million with net debt to EBITDA at 3.46. When we switch over and look at the enterprise to sales, we see a ratio of 3.55. The receivables turnover for the company is 15.43for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
To sum up, Kiniksa Pharmaceuticals International Plc (KNSA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
